A balancing act

dual immune-checkpoint inhibition for oesophagogastric cancer

Kazuto Harada, Ahmed A.F. Abdelhakeem, Jaffer A Ajani

Research output: Contribution to journalComment/debate

Abstract

A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.

Original languageEnglish (US)
Pages (from-to)9-10
Number of pages2
JournalNature Reviews Clinical Oncology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

CD274 Antigen
Adenocarcinoma
Biomarkers
Morbidity
Mortality
Neoplasms
nivolumab
ipilimumab

ASJC Scopus subject areas

  • Oncology

Cite this

A balancing act : dual immune-checkpoint inhibition for oesophagogastric cancer. / Harada, Kazuto; Abdelhakeem, Ahmed A.F.; Ajani, Jaffer A.

In: Nature Reviews Clinical Oncology, Vol. 16, No. 1, 01.01.2019, p. 9-10.

Research output: Contribution to journalComment/debate

@article{84a1831786b24c2090dffcc4f700643d,
title = "A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer",
abstract = "A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.",
author = "Kazuto Harada and Abdelhakeem, {Ahmed A.F.} and Ajani, {Jaffer A}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41571-018-0108-x",
language = "English (US)",
volume = "16",
pages = "9--10",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A balancing act

T2 - dual immune-checkpoint inhibition for oesophagogastric cancer

AU - Harada, Kazuto

AU - Abdelhakeem, Ahmed A.F.

AU - Ajani, Jaffer A

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.

AB - A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.

UR - http://www.scopus.com/inward/record.url?scp=85054528618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054528618&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0108-x

DO - 10.1038/s41571-018-0108-x

M3 - Comment/debate

VL - 16

SP - 9

EP - 10

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 1

ER -